More News of Interest

TriGUARD 3™ Cerebral Embolic Protection Device Receives CE Mark for Use in Transcatheter Heart Procedures

Doctor Nicolas Dumonteil, Interventional Cardiologist, Clinique Pasteur in Toulouse, France notes, “Even with increased operator experience and availability of next-generation TAVI devices, cerebrovascular complications remain at a stable level, but continue to be the most feared and devastating complications during TAVI. ” He added, “Interventional cardiologists are seeking options to avoid cerebral complications for their patients.”

TriGUARD 3™ Cerebral Embolic Protection Device is the only CE Marked product designed to cover and protect all three major cerebral aortic arch vessels. The state-of-the-art Nitinol frame and dome-shaped mesh deflector are delivered transfemorally and designed to “self-position” in the aortic arch.  This design allows the TriGUARD 3™ CEP device to conform to a variety of patient anatomies.

“Taking into consideration the devastating impact of stroke, we are pleased to bring this important technology to patients undergoing any transcatheter heart procedure.  The introduction of the TriGUARD 3™ CEP Device in Europe provides physicians the only commercially available device that is designed to protect all three cerebral vessels.” Stated Chris Richardson, Keystone Heart, President and CEO.

Keystone Heart recently completed the REFLECT Trial (a pivotal randomized trial of the TriGUARD 3™ CEP device).  Keystone Heart is currently finalizing data analysis ahead of the planned marketing application to the US Food and Drug Administration.

Latest Posts

Don't Miss